March 2024 Patent Highlights: OX2R Agonists, TEAD Covalent Inhibitors, NaV1.8 Inhibitors, LRRK2 Inhibitors, and More
Other articles you may be interested in
Drug Hunter Annotated Patent Database Search
As part of our series of monthly patent roundup articles, which bring you highlights of the most relevant drug discovery IP disclosures, by member request we have collated recent selections into a single searchable table. This tool allows you to see longer-term industry trends in therapeutic areas and target selection to inspire ideas for your pipeline.
Monte Rosa's Molecular Glue Degraders of VAV1 Exploit a Non-Canonical Degron
This article highlights a patent application from Monte Rosa Therapeutics that discloses the biological activity of compounds that act as VAV1 molecular glue degraders, providing a summary of key data for selected molecules disclosed in the patent application.
Key Clinical Compound Updates from August 2024
Here’s a rundown of August’s key clinical developments, including FDA approvals, potential upcoming approvals, notable trial readouts, new NDA submissions, and pipeline realignments.
July’s Molecules on the Move
To get you up to speed, here’s a recap of July’s molecules on the move, including potential upcoming approvals, key interim trial readouts, new IND submissions, and trial setbacks.
July 2024 Molecule Roundup | 50 Molecules from July to Know
In this article, you'll find a curated selection of nearly 50 molecules from July that piqued our interest, highlights of some of our favorites, and explanations of why they're worth watching.